A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Public ClinicalTrials.gov record NCT04929223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Study identification
- NCT ID
- NCT04929223
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 542 participants
Conditions and interventions
Conditions
Interventions
- Inavolisib Drug
- Bevacizumab Drug
- Cetuximab Drug
- Atezolizumab Drug
- Tiragolumab Drug
- SY-5609 Drug
- Divarasib Drug
- FOLFOX Drug
- FOLFIRI Drug
- FoundationOne®Liquid CDx Diagnostic Test
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2021
- Primary completion
- Aug 30, 2030
- Completion
- Aug 30, 2030
- Last update posted
- Aug 16, 2026
2021 – 2030
United States locations
- U.S. sites
- 35
- U.S. states
- 18
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Comprehensive Cancer Center | Birmingham | Alabama | 35233 | Withdrawn |
| Mayo Clinic Arizona | Phoenix | Arizona | 85259 | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | Recruiting |
| cCare | Encinitas | California | 92024 | Withdrawn |
| USC Norris Cancer Center | Los Angeles | California | 90033 | Completed |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Recruiting |
| UCLA | Los Angeles | California | 90095 | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Withdrawn |
| Stanford Cancer Center | Stanford | California | 94305-5820 | Completed |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Lone Tree | Colorado | 80124 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Eastern Ct Hema/Onco Assoc | Norwich | Connecticut | 06360 | Withdrawn |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | Recruiting |
| Mary Bird Perkins Cancer Ctr | Baton Rouge | Louisiana | 70809 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114-2621 | Completed |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Withdrawn |
| Mayo Clinic Rochester | Rochester | Minnesota | 55902 | Recruiting |
| New York Cancer & Blood Specialists - New Hyde Park | New Hyde Park | New York | 11042-1116 | Recruiting |
| New York Cancer and Blood Specialists-Central Park Hematology & Oncology | New York | New York | 10028 | Recruiting |
| New York Cancer & Blood Specialists | Port Jefferson Station | New York | 11776 | Recruiting |
| New York Cancer & Blood Specialists - Bronx | The Bronx | New York | 10469-5930 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Completed |
| Hematology Oncology Salem | Salem | Oregon | 97301 | Recruiting |
| UPMC - Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Active, not recruiting |
| Sarah Cannon Research Institute / Tennessee Oncology | Nashville | Tennessee | 37203 | Completed |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Completed |
| Texas Oncology - Northeast Texas | Denton | Texas | 76201 | Recruiting |
| Lumi Research | Kingwood | Texas | 77339 | Withdrawn |
| Texas Oncology - Gulf Coast | Webster | Texas | 77598-4420 | Recruiting |
| Swedish Cancer Inst. | Seattle | Washington | 98104 | Completed |
| Medical Oncology Associates | Spokane | Washington | 99208 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04929223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04929223 live on ClinicalTrials.gov.